Testing dasatinib in children with very high-risk acute lymphoblastic leukemia
Compares dasatinib with other treatment in children with very high-risk leukemia.
Plain-language title generated from the registry record
Registry title: Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea
Key facts
- Where
- Daegu, Daejeon, Hwasun, Jeju City, Seoul, and Yangsan, South KoreaSee the 10 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 1 and 19 years old?
Source: NCT06257394, who can take part
Where in South Korea
- Kyungpook National University Chilgok HospitalDaegu, South KoreaTaking people
- Chungnam National University HospitalDaejeon, South KoreaTaking people
- Chonnam National University Hwasun HospitalHwasun, South KoreaTaking people
- Jeju National University HospitalJeju City, South KoreaTaking people
- Asan Medical CenterSeoul, South KoreaTaking people
- Samsung Medical CenterSeoul, South KoreaTaking people
- Seoul National University HospitalSeoul, South KoreaTaking people
- Seoul saint Mary's HospitalSeoul, South KoreaTaking people
- Severance hospitalSeoul, South KoreaTaking people
- Pusan National University Yangsan HospitalYangsan, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hyoung Jin Kang
- Trial code
- NCT06257394
- Record updated
- 29 July 2026
- Original description
Very high-risk acute lymphoblastic leukemiaRead full original descriptionShow less
Multi-center Clinical Trial for Optimal Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea
Very high-risk acute lymphoblastic leukemia
Inclusion: Pediatric patients diagnosed with ALL between the ages of 1 and 19 years at the time of diagnosis who meet one or more of the following conditions:; Philadelphia chromosome-positive t(9;22)(q34;q11) or; Patients with failed remission who had blast > 5% on bone marrow test after initial remission induction therapy or; Hypodiploidy (Number of chromosomes \< 44 (less than 44)) or; E2A-HLF(Hepatic Leukemia Factor) translocation-positive or; When the prognosis is judged to be poor according to NGS-MRD results among high-risk ALL patients (i) In B-ALL, the NGS-MRD(Next Generation Sequencing-Minimal Residual Disease) after consolidation therapy is 0.01% or more, and the NGS-MRD followed during interim maintenance treatment is also 0.01% or more, (ii) In T-ALL, NGS-MRD(Next Generation Sequencing-Minimal Residual Disease) is more than 0.01% after consolidation therapy.
Exclusion: Participants with contraindications to medications; When the study participant or their legal representative withdraws consent; Pregnant or lactating women (patients of child-bearing potential require adequate contraception during the study period); Participants who are medically unsuitable to participate in this study at the discretion of the investigator Participants participating in other interventional studies other than this protocol.